Next generation therapies change the landscape in melanoma

by Flaherty, Keith T.
Published 2011

When are signal transduction targeted therapies acting as immunotherapy?

by Flaherty, Keith T
Published in Cancer Biol Ther (2015)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

by Sullivan, Ryan J., Flaherty, Keith T.
Published 2011

Moving treatments earlier to move further forward

by Davies, Michael A., Flaherty, Keith T.
Published in Nat Rev Clin Oncol (2017)

Targeting the RAS pathway in melanoma

by Ji, Zhenyu, Flaherty, Keith T., Tsao, Hensin
Published 2011

Biological challenges of BRAF inhibitor therapy

by Puzanov, Igor, Burnett, Patrick, Flaherty, Keith T.
Published in Mol Oncol (2011)

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

by Bai, Xue, Fisher, David E., Flaherty, Keith T.
Published in Nat Rev Clin Oncol (2019)

Mutation-driven drug development in melanoma

by Flaherty, Keith T., Hodi, F. Stephen, Bastian, Boris C.
Published 2010

Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

by Wargo, Jennifer A., Cooper, Zachary A., Flaherty, Keith T.
Published in Cancer Discov (2014)

Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma

by Verduzco, Daniel, Flaherty, Keith T., Smalley, Keiran S.M.
Published in Exp Dermatol (2015)

YAP in MAPK pathway targeted therapy resistance

by Flaherty, Keith T, Wargo, Jennifer A, Bivona, Trever G
Published in Cell Cycle (2015)

Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy

by Lo, Jennifer A., Fisher, David E., Flaherty, Keith T.
Published in JAMA Oncol (2015)

Mechanisms of resistance to immune checkpoint inhibitors

by Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
Published in Br J Cancer (2018)

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be

by Sullivan, Ryan J., LoRusso, Patricia M., Flaherty, Keith T.
Published 2013

The Conundrum of Genetic “Drivers” in Benign Conditions

by Kato, Shumei, Lippman, Scott M., Flaherty, Keith T., Kurzrock, Razelle
Published in J Natl Cancer Inst (2016)

Melanoma: New Insights and New Therapies

by Nikolaou, Vasiliki A., Stratigos, Alexander J., Flaherty, Keith T., Tsao, Hensin
Published 2012

Precision medicine for cancer with next-generation functional diagnostics

by Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.
Published in Nat Rev Cancer (2015)

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

by Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
Published in Oncotarget (2015)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

by Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
Published in J Invest Dermatol (2015)

A Melanoma Molecular Disease Model

by Vidwans, Smruti J., Flaherty, Keith T., Fisher, David E., Tenenbaum, Jay M., Travers, Michael D., Shrager, Jeff
Published 2011